BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026

MT Newswires Live

06/01

BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.

The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.

Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.

BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2640955081"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640955081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640955081?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640955081","market":"sh","top_or_hot":-1,"title":"BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-01 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.</p><p>The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.</p><p>Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.</p><p>BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640955081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640955081","pubTimestamp":1780312221,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines  said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州","MDCO":"麦迪逊医药","BK4139":"生物科技","BK4526":"热门中概股","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"BeOne Medicines表示其实验性癌症疗法在ASCO 2026上显示出“有希望”的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ONC":1},"content_text":"BeOne Medicines (ONC) said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}